Masha Niv: Bitter Taste Receptors and the Drug Discovery Blind Spot

Taste receptors are among the most overlooked GPCRs in pharmacology - and Masha Niv has spent her career building the tools to change that. This conversation explores the biology, diversity, and unexpected reach of human taste GPCRs, beginning with the 25-subtype family of bitter taste receptors and extending into sweet receptor signaling, extraoral tissue expression, and the emerging science of taste-based drug prediction.

Niv describes how bitter taste receptors differ structurally from most other GPCRs - missing conserved motifs, more prone to activation, and resistant to pharmacological blockade - and why those properties have shaped both the therapeutic opportunities and the research challenges her lab works on. She traces the receptor-ligand matchmaking problem at the heart of the field: 25 subtypes, thousands of known bitter compounds, and a network of associations that a machine learning recommendation system is now beginning to map.

The conversation also covers what happens when taste pharmacology intersects with drug development - a collision that, for most of pharmaceutical history, has occurred too late. Niv's early exposure to bitterness as a formulation problem rooted her work in a question that still matters every time a patient refuses a pill.

ABOUT THE GUEST

Masha Niv is associate professor and vice dean of research and development at the Hebrew University of Jerusalem's Faculty of Agriculture, Food and Environment, located in Rehovot. A computational pharmacologist by training, she built BitterDB - the first dedicated database of bitter compounds - and has mapped the structural and chemical properties governing ligand promiscuity across all 25 human bitter taste receptor subtypes. Her lab uses homology modeling, machine learning, and collaborative sensory experiments to predict bitterness, identify antagonists, and understand how taste GPCRs function in tissues far from the tongue. She was also a key contributor to the GCCR consortium's large-scale chemosensory research during the COVID-19 pandemic.

SCIENTIFIC THEMES OF THE CONVERSATION

1. The architecture of bitter taste receptor diversity - 25 subtypes, ligand promiscuity, and the challenge of orphan receptors with no known ligand
   

2. Extraoral expression of taste GPCRs - physiological roles in the airways, gut, heart, and cancer tissues
   

3. Receptor-ligand matchmaking - applying recommendation system logic to the bitter taste receptor family
   

4. Sweet taste receptor biology and the heavy water paradox - what a single atomic substitution reveals about receptor sensitivity
   

5. Bitterness as a drug development variable - machine learning prediction, formulation consequences, and the FDA's late entry into the conversation
   

6. COVID-19 and chemosensory science - how a global consortium formed from a handful of tweets and what it found about taste and smell loss

KEY INSIGHTS FROM THE CONVERSATION

1. Bitter taste receptors are built to activate, not to be blocked

Bitter taste GPCRs are structurally unusual within the broader GPCR family - they lack several conserved motifs and disulfide bridges present in most other subfamilies. Niv argues this architecture reflects evolutionary logic: a receptor whose job is to detect potential toxins before consumption should be maximally sensitive to activation. The cost is that finding antagonists for these receptors has proven far more difficult than finding agonists, a pharmacological asymmetry her lab is actively working to resolve.

2. Bitterness and toxicity are not the same thing - and the field had to prove it

A long-standing assumption in both traditional medicine and drug development treated bitterness as a proxy for toxicity. Niv's work directly challenged that correlation: many intensely bitter compounds are non-toxic, and many toxic compounds are not bitter at all. Recognizing that distinction opened space for a more nuanced view of bitter compounds in nutrition and pharmacology - including the possibility that some bitterness in diet is associated with health benefit, not harm.

3. The drug bitterness blind spot persisted for decades because no one built the right tool early enough

Drug discovery workflows screen extensively for efficacy, safety, and pharmacokinetics - but bitterness prediction was rarely incorporated until clinical or even post-market stages. Niv's lab developed a machine learning predictor trained on intensely bitter compounds that can flag bitterness risk from chemical structure alone, early in the development pipeline. The FDA recently made taste reporting a formal requirement, a regulatory shift Niv sees as overdue.

4. A single atomic change in water is enough to activate the sweet taste receptor

Deuterated water - in which hydrogen is replaced by the heavier isotope deuterium - produces a measurable sweet signal in sensory experiments. Niv's lab showed that this response depends on the T1R2/T1R3 heterodimer sweet taste receptor: a known receptor inhibitor suppresses the sweetness of heavy water. What makes this finding unusual is the magnitude of the effect relative to the size of the chemical change - the mechanism is still under investigation, but the receptor involvement is established.

5. Taste receptor expression throughout the body reshapes the meaning of drug off-targets

Bitter taste receptors are expressed not only in taste receptor cells on the tongue but in the upper airways, gut, heart, and certain cancer tissues. This extraoral distribution has practical consequences: drugs targeting other receptors may be inadvertently activating bitter taste GPCRs in the lung or intestine, contributing to effects that were never attributed to the right target. Niv sees this as one of the more underexplored dimensions of polypharmacology.

6. COVID-19 taste loss was a scientific detour that became something larger

Niv had not planned to work on COVID-19 - she had never worked on viruses and was cautious about entering a field she did not know. When reports of taste impairment emerged, she felt obligated to contribute. A small cluster of Twitter exchanges became email threads, became a Slack workspace, became the GCCR consortium - a rapid-assembly international collaboration that surveyed tens of thousands of patients and found that while both smell and taste are impaired in the majority of symptomatic cases, smell loss is the stronger diagnostic signal.

7. The matchmaking problem - and why recommendation systems belong in receptor pharmacology

With 25 subtypes, thousands of known bitter ligands, and a matrix of partial associations, the question of which compound activates which receptor is too large and too sparse for classical screening alone. Niv's lab is developing a recommendation system - trained on known receptor-ligand pairs and the structural properties of both - that can suggest candidate receptors for any new compound. The analogy she uses is direct: the system works the way a streaming platform learns your preferences from what similar users have watched.

EPISODE TIMELINE

Note: Timestamps below are AI-generated from the episode transcript and are approximate. Exact times may vary slightly from the final edited audio or video.

00:00 - Introduction and Dr. GPCR announcements

01:26 - Niv's career path - from theoretical chemistry in Russia and Israel to biotech, then a Cornell postdoc

08:03 - Choosing taste GPCRs as a research focus - how the arrival of GPCR structures made this the right moment

10:49 - The bitter taste receptor family - 25 subtypes, BitterDB, and the receptor-ligand matchmaking challenge

15:53 - Extraoral expression - bitter taste receptors in the airways, gut, heart, and cancer tissues

19:37 - Sweet taste receptors and an unexpected result - heavy water activates the T1R2/T1R3 heterodimer

23:53 - COVID-19 and chemosensory loss - how a global research consortium assembled from a handful of tweets

31:01 - The formulation problem - when a clinically effective drug fails because no one screened for bitterness

38:55 - Why bitter taste GPCRs resist antagonists - structural architecture and pharmacological consequences

41:58 - Taste GPCRs as drug targets - asthma, cardiac physiology, and early signals in cancer biology

44:18 - Rethinking bitterness in nutrition - the case for accepting bitter compounds in Western diet

50:13 - Advice for junior scientists and resources for the GPCR community

SELECTED QUOTES

About this episode

Dr. Niv is currently an associate professor and vice dean for research at the Hebrew University of Jerusalem. The Niv lab is also part of the Global Consortium for Chemosensory Research. Masha earned her Bachelor’s degree in chemistry, followed by a direct Ph.D. at the Institute of Chemistry, at The Hebrew University of Jerusalem in Israel. Dr. Niv trained as a postdoctoral fellow at Weill Cornell Medical College. Her work focuses on both sweet and bitter taste receptor GPCRs and her lab established the BitterDB.

Dr. Masha Niv on the web

• Niv Lab

• LinkedIn

• Twitter

• Pubmed

• Google Scholar

• Dr. GPCR Ecosystem